| Table 2. Comparison of ovarian stimulation data and outcomes between women who underwent elective fertility preservation before and after the outbreak of the Covid-19 pandemic. | |||
| Characteristic | Before Covid-19 (n=123) |
After Covid-19 (n=451) |
p value |
|---|---|---|---|
| Protocol type GnRH antagonist Short GnRH agonist PPOS |
121 (98.4%) 2 (1.6%) 0 |
357 (79.2%) 9 (2%) 85 (18.8%) |
< 0.001 |
| Ovarian stimulation duration (days) | 10.9 (1.67) | 11.2 (1.67) | 0.069 |
| GT total dose (mIU/mL) | 3426.5 (1080.63) | 3164.6 (842.87) | 0.014 |
| Peak E2 (pg/mL) | 2680.2 (2101.53) | 2752.2 (2322.03) | 0.606* |
| Peak P (ng/mL) | 1.3 (1.02) | 1.1 (0.63) | 0.575* |
| Final maturation trigger GnRH agonist hCG hCG+GnRH agonist |
110 (89.4%) 12 (9.8%) 1 (0.8%) |
424 (94%) 21 (4.7%) 6 (1.3%) |
0.091 |
| Oocytes retrieved | 16.4 (12.03) | 15 (10.51) | 0.545* |
| MII oocytes | 13.1 (10.22) | 11.7 (8.61) | 0.364* |
| Oocyte maturity rate | 78.1 (17.27) | 77.4 (18.11) | 0.719 |
| Embryo cryopreservation No Yes |
111 (90.2%) 12 (9.8%) |
410 (90.9%) 41 (9.1%) |
0.861 |
| Sperm origin Donor Partner |
11 (91.7%) 1 (8.3%) |
31 (75.6%) 10 (24.4%) |
0.421 |
Values are presented as mean (standard deviation) or number (%). A p value of <0.05 was considered significant.
*The p value was calculated after log transformation for normal distribution.
GnRH, gonadotropin-releasing hormone; PPOS, progestin-primed ovarian stimulation; GT, gonadotropins; E2, estradiol; P, progesterone; hCG, human chorionic gonadotropin; MII, metaphase II.